Market Overview

Benzinga's Top Downgrades

Share:
Related BMRN
The FDA Just Crushed Sarepta Therapeutics' Hopes Of Releasing A Muscular Dystrophy Drug
Why BioMarin's Pipeline Could Be Worth $4 Billion-Plus
Recent Setbacks Have Duchenne Investors On Edge (Seeking Alpha)
Related PEG
Morgan Stanley Upgrades Regulated Utilities Sector; Dynegy Is Top Pick, Laclede, Pinnacle West Downgraded
Earnings Scheduled For October 30, 2015
Even Income Stocks Can Form Bases; Look At These Utilities (Investor's Business Daily)

Analysts at Deutsche Bank downgraded BioMarin Pharmaceutical (NASDAQ: BMRN) from “buy” to “hold.” BioMarin's shares closed at $38.70 on Friday. BioMarin's trailing-twelve-month ROE is -11.59%.

Analysts at FBR Capital downgraded Public Service Enterprise Group (NYSE: PEG) from “market perform” to “underperform.” PSEG's stock closed at $32.13 on Friday. PSEG's PEG ratio is 6.66.

Analysts at KeyBanc Capital downgraded Ignite Restaurant Group (NASDAQ: IRG) from “buy” to “hold.” Ignite Restaurant's shares closed at $15.12 on Friday. Ignite Restaurant's trailing-twelve-month profit margin is 2.99%.

UBS downgraded Westlake Chemical (NYSE: WLK) from “neutral” to “sell.” Westlake Chemical's shares closed at $69.50 on Friday. Westlake Chemical's trailing-twelve-month ROA is 9.24%.

Latest Ratings for BMRN

DateFirmActionFromTo
Jan 2016Credit SuisseInitiates Coverage onOutperform
Jan 2016BarclaysMaintainsOverweight
Nov 2015Goldman SachsInitiates Coverage onBuy

View More Analyst Ratings for BMRN
View the Latest Analyst Ratings

Posted-In: Top DowngradesDowngrades Analyst Ratings

 

Related Articles (BMRN + IRG)

View Comments and Join the Discussion!

Get Benzinga's Newsletters